{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-001486","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.706596+00:00","generated_at":"2026-05-24T02:46:34.289032+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enveric Biosciences Q4 2024 net loss $3.2M, cash $2.2M; out-licenses up to $144M","bullets":["Net loss $3.2M for Q4 2024; diluted EPS loss $4.83; cash-on-hand $2.2M.","Out-licensing deals with Aries ($61M milestones), MycoMedica ($62M), Restoration Biologics ($82M).","Lead candidate EB-003 confirmed oral bioavailability and brain exposure; pre-IND activities ongoing.","Closed $5M public offering in 2024 to fund development."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-001486","json":"https://secwatch.observer/filing/0001641172-25-001486.json","markdown":"https://secwatch.observer/filing/0001641172-25-001486.md","text":"https://secwatch.observer/filing/0001641172-25-001486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000164117225001486/0001641172-25-001486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000164117225001486/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:46:34.289032+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}